Market Overview

Loncar China BioPharma ETF (CHNA) Launches on Nasdaq

Share:

CHNA offers diversified exposure to leading companies in China's
burgeoning BioPharma industry

Today, the Loncar
China BioPharma ETF
(NASDAQ:CHNA) begins trading on the Nasdaq in
the United States. The CHNA ETF seeks to give investors access to
China's rapidly-developing biopharmaceutical industry. It is based on
the Loncar China BioPharma Index, an innovative index developed by
biotechnology investor Brad Loncar.

Exchange Traded Concepts (ETC) partnered with Loncar Investments on the
successful launch of the fund. It invests in 28 companies, 22 of which
are listed on the Hong Kong Stock Exchange and six of which are listed
on Nasdaq, offering investors distinct, global exposure through the
convenience of one security.

"China aims to become a leader in global medicine," said Brad Loncar,
Chief Executive Officer of Loncar Investments. "Regulatory reform and a
new rule allowing pre-revenue biotech companies to list on the Hong Kong
Stock Exchange may signal a new era for innovative drug development in
the region. We think this is an important trend in healthcare, as it has
the potential to spur growth and benefit patients worldwide."

"We are proud to deliver another cutting-edge, biotech-focused product
to the market," said J. Garrett Stevens, CEO of Exchange Traded
Concepts. "China's goal of moving its life sciences industry towards
innovation is one of the most exciting themes within biotechnology, and
the Loncar China BioPharma ETF gives investors a front row seat to this
transformation."

CHNA comes at an expense ratio of 0.79 percent. It joins the Loncar
Cancer Immunotherapy ETF (NASDAQ:CNCR) under the Loncar Funds brand of
innovative biotechnology-focused ETFs. For more information about these
products, please visit http://www.loncarfunds.com.

About Exchange Traded Concepts: ETC is carving out a niche as a
portal to launch new, custom exchange-traded funds efficiently and
cost-effectively through a complete turnkey solution. ETC is a
private-label ETF advisor with passive and active exemptive relief from
the Securities and Exchange Commission (SEC) to launch both domestic and
international equity exchange traded funds under the Investment Company
Act of 1940. For more information, please go to www.exchangetradedconcepts.com.

About Loncar Investments: Loncar Investments, LLC is committed to
making the biotechnology space more approachable to a wider range of
investors. It incorporates extensive research into biotech companies and
technologies to develop stock market indexes that are focused on precise
investment opportunities. Its first two indexes are the Loncar Cancer
Immunotherapy Sector Index (LCINDX) and the Loncar China BioPharma
Industry Index (LCHINA). The company is principally owned by biotech
investor and analyst Brad Loncar.

Opinions expressed are those of ETC and Loncar Investments are subject
to change, not guaranteed, and should not be considered investment
advice.

Investing involves risk; Principal loss is possible. CNCR will invest
in immunotherapy companies which are highly dependent on the
development, procurement and marketing of drugs and the protection and
exploitation of intellectual property rights. A company's valuation can
also be greatly affected if one of its products is proven or alleged to
be unsafe, ineffective or unprofitable. The costs associated with
developing new drugs can be significant, and the results are
unpredictable. The process for obtaining regulatory approval by the U.S.
Food and Drug Administration or other governmental regulatory
authorities is long and costly and there can be no assurance that the
necessary approvals with be obtained and maintained. The Fund may invest
in foreign securities, which involve political, economic, currency risk,
greater volatility, and differences in accounting methods. The Fund is
non-diversified meaning it may concentrate its assets in fewer
individual holdings than a diversified fund. Therefore, the Fund is more
exposed to individual stock volatility than a diversified fund. The Fund
invests in smaller companies which may have more limited liquidity and
greater volatility compared to larger companies. The Fund is not
actively managed and may be affected by a general decline in market
segments related to the index. The fund invests in securities included
in, or representative of securities included in, the index, regardless
of their investment merits. The performance of the fund may diverge from
that of the Index and may experience tracking error to a greater extent
than a fund that seeks to replicate an index.

Shares of any ETF are bought and sold at market price (not NAV), may
trade at a discount or premium to NAV and are not individually redeemed
from the Fund. Brokerage commissions will reduce returns. The
biopharmaceutical industry in China is strictly regulated and changes in
such regulations, including banning or limiting certain products, may
have a material adverse effect on the operations, revenues, and
profitability of Biopharma Companies. The laws and regulations
applicable to the process of administrative approval of medicine and its
production in China require entities producing biopharma products to
comply strictly with certain standards and specifications promulgated by
the government. To the extent the Fund invests a significant portion of
its assets in the securities of companies of a single country or region,
such as China, it is more likely to be impacted by events or conditions
affecting that country or region. A significant portion of the Fund's
assets will be invested in the biotechnology and pharmaceutical
industries, which expose the Fund to the risks of the following sector.
Companies in the health care sector are subject to extensive government
regulation. The costs associated with developing new drugs can be
significant, and the results are unpredictable. Newly developed drugs
may be susceptible to product obsolescence due to intense competition
from new products and less costly generic products. The process for
obtaining regulatory approval by the U.S. Food and Drug Administration
or other governmental regulatory authorities is long and costly and
there can be no assurance that the necessary approvals will be obtained
or maintained. The values of many companies in the health care sector
may be significantly affected by such things as the expiration of
patents or the loss of, or the inability to enforce, intellectual
property rights.

The Fund's investment objectives, risks, charges and expenses must be
considered carefully before investing.
The summary and statutory
prospectuses contain this and other important information about the
investment company, and may be obtained by calling 800.617.0004 or
visiting
www.loncarfunds.com.
Read it carefully before investing.

Fund holdings are subject to change and should not be considered a
recommendation to buy or sell any security.

The Loncar Cancer Immunotherapy Sector Index is an index of 25
securities that have a strategic focus on the area of cancer
immunotherapy, or harnessing the immune system to fight cancer. Quotes
for the index can be found under the symbol "LCINDX" on the Bloomberg
Professional service and other financial data providers. One may not
directly invest in an index.

The Loncar China BioPharma Industry Index is an index of 28 securities
that have a strategic focus on developing China's biopharmaceutical
industry. Quotes for the index can be found under the symbol "LCHINA" on
the Bloomberg Professional service and other financial data providers.

The Hong Kong Stock Exchange is the primary stock exchange in the Hong
Kong Special Administrative Region of China. Nasdaq is one of the
primary stock exchanges in the United States.

One may not directly invest in an index.

Diversification does not assure a profit nor protect against loss in
a declining market.

The SEC does not approve or disapprove of any investment. (www.sec.gov).

Exchange Traded Concepts, LLC serves as the investment advisor to the
Funds. The Loncar China BioPharma ETF and the Loncar Cancer
Immunotherapy ETF are distributed by Quasar Distributors, LLC, which is
not affiliated with Exchange Traded Concepts, LLC or any of its
affiliates.

View Comments and Join the Discussion!